Highlights
- •A number of high-penetrance genes are associated with breast cancer.
- •Radiation in patients with BRCA1/2 carriers does not increase risk of contralateral breast cancer.
- •TP53 carriers have considerable risk of secondary malignancy.
- •Radiation does not increase risk of adverse effects in carriers of pathogenic ATM variants.
Abstract
The diagnosis of hereditary or familial breast cancers influences the locoregional
approach to breast cancer, with most patients undergoing mastectomy to avoid or minimize
the use of adjuvant radiation therapy. We evaluated the current literature about known
high- and moderate-penetrance genes and studied their impact on local control, toxicities,
and contralateral breast cancers after adjuvant radiation therapy. The aim is to encourage
the safe use of adjuvant radiation therapy when indicated in concordance with the
updated guidelines.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Radiotherapy and OncologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Management of Hereditary Breast Cancer: American Society of Clinical Oncology, American Society for Radiation Oncology, and Society of Surgical Oncology Guideline.J Clin Oncol Off J Am Soc Clin Oncol. 2020; 38: 2080-2106
- Comprehensive molecular portraits of human breast tumours.Nature. 2012; 490: 61-70
- Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence.Am J Hum Genet. 1995; 57: 1457-1462
- Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers.JAMA. 2017; 317: 2402-2416
- Meta-analysis of BRCA1 and BRCA2 penetrance.J Clin Oncol Off J Am Soc Clin Oncol. 2007; 25: 1329-1333
- New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.Science. 2003; 302: 643-646
- Frequency of Germline Mutations in 25 Cancer Susceptibility Genes in a Sequential Series of Patients With Breast Cancer.J Clin Oncol Off J Am Soc Clin Oncol. 2016; 34: 1460-1468
- ATM Variants in Breast Cancer: Implications for Breast Radiation Therapy Treatment Recommendations.Int J Radiat Oncol Biol Phys. 2021; 110: 1373-1382
- Health risks for ataxia-telangiectasia mutated heterozygotes: a systematic review, meta-analysis and evidence-based guideline.Clin Genet. 2016; 90: 105-117
- The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.The BMJ. 2021; 29: n71
- The Implications of Genetic Testing on Radiation Therapy Decisions: A Guide for Radiation Oncologists.Int J Radiat Oncol. 2019; 105: 698-712
- BRCA1/2 Mutation-associated Breast Cancer, Wide Local Excision and Radiotherapy or Unilateral Mastectomy: A Systematic Review.Clin Oncol R Coll Radiol G B. 2015; 27: 527-535
- Clinical relevance of normal and tumour cell radiosensitivity in BRCA1/BRCA2 mutation carriers: A review.The Breast. 2015; 24: 100-106
- Response to radiation therapy and prognosis in breast cancer patients with BRCA1 and BRCA2 mutations.Radiother Oncol J Eur Soc Ther Radiol Oncol. 1998; 47: 129-136
- Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations.J Clin Oncol Off J Am Soc Clin Oncol. 2000; 18: 3360-3369
- Late toxicity is not increased in BRCA1/BRCA2 mutation carriers undergoing breast radiotherapy in the United Kingdom.Clin Cancer Res Off J Am Assoc Cancer Res. 2006; 12: 7025-7032
- The Influence of BRCA1/BRCA2 Mutations on Toxicity Related to Chemotherapy and Radiotherapy in Early Breast Cancer Patients.Oncology. 2013; 85: 278-282
- Acute skin toxicity in Korean breast cancer patients carrying BRCA mutations.Int J Radiat Biol. 2014; 90: 90-94
- Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.J Natl Cancer Inst. 1999; 91: 2112-2117
- Ten-year multi-institutional results of breast-conserving surgery and radiotherapy in BRCA1/2-associated stage I/II breast cancer.J Clin Oncol Off J Am Soc Clin Oncol. 2006; 24: 2437-2443
- Tumour characteristics, survival and prognostic factors of hereditary breast cancer from BRCA2-, BRCA1- and non-BRCA1/2 families as compared to sporadic breast cancer cases.Eur J Cancer Oxf Engl. 2007; 43: 867-876
- Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.Breast Cancer Res Treat. 2010; 120: 119-126
- Prognostic Impact of Breast-Conserving Therapy Versus Mastectomy of BRCA1/2 Mutation Carriers Compared With Noncarriers in a Consecutive Series of Young Breast Cancer Patients.Ann Surg. 2019; 270: 364-372
- Risk of ipsilateral breast tumor recurrence in primary invasive breast cancer following breast-conserving surgery with BRCA1 and BRCA2 mutation in China.Breast Cancer Res Treat. 2019; 175: 749-754
- Analysis of Outcomes in Patients With BRCA1/2 Breast Cancer Mutations Treated With Accelerated Partial Breast Irradiation (APBI).Am J Clin Oncol. 2019; 42: 446-453
- Locoregional Treatments and Ipsilateral Breast Cancer Recurrence Rates in BRCA1/2 Mutation Carriers.Int J Radiat Oncol. 2021; 109: 1332-1340
- Predictors of contralateral breast cancer in BRCA1 and BRCA2 mutation carriers.Br J Cancer. 2011 Apr 26; 104: 1384-1392
- Adjuvant radiotherapy for primary breast cancer in BRCA1 and BRCA2 mutation carriers and risk of contralateral breast cancer with special attention to patients irradiated at younger age.Breast Cancer Res Treat. 2015; 154: 171-180
- Radiation-Associated Secondary Malignancies in BRCA Mutation Carriers Treated for Breast Cancer.Int J Radiat Oncol. 2020; 107: 353-359
- Radiation Treatment, ATM, BRCA1/2, and CHEK2*1100delC Pathogenic Variants and Risk of Contralateral Breast Cancer.JNCI J Natl Cancer Inst. 2020; 112: 1275-1279
- Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.LancetLond Engl. 2002; 359: 1471-1477
- Ipsilateral breast tumour recurrence in hereditary breast cancer following breast-conserving therapy.Eur J Cancer Oxf Engl. 2004; 40: 1150-1158
- Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?.Ann Surg Oncol. 2009; 16: 3380-3387
- Local therapy in BRCA1 and BRCA2 mutation carriers with operable breast cancer: comparison of breast conservation and mastectomy.Breast Cancer Res Treat. 2010; 121: 389-398
- Contralateral Breast Cancer after Radiotherapy among BRCA1 and BRCA2 Mutation Carriers: A WECARE Study Report.Eur J Cancer Oxf Engl. 2013; 49: 2979-2985
- High risk of in-breast tumor recurrence after BRCA1/2-associated breast cancer.Breast Cancer Res Treat. 2014; 147: 571-578
- A combined analysis of outcome following breast cancer: differences in survival based on BRCA1/BRCA2 mutation status and administration of adjuvant treatment.Breast Cancer Res. 2003; 6: R8
- Current role of modern radiotherapy techniques in the management of breast cancer.World J Clin Oncol. 2014; 5: 425-439
- Factors Associated with Late Local Radiation Toxicity after Post-Operative Breast Irradiation.Breast J. 2022; 2022: 6745954
- Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.Int J Clin Oncol. 2021; 26: 2161-2178
- Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome.Radiat Oncol Lond Engl. 2010; 8: 104
- Two metachronous tumors in the radiotherapy fields of a patient with Li-Fraumeni syndrome.Int J Cancer. 2001; 96: 238-242
- Rapid Development of Post-radiotherapy Sarcoma and Breast Cancer in a Patient with a Novel Germline ‘De-Novo’ TP53 Mutation.Clin Oncol. 2007; 19: 490-493
- Chest wall leiomyosarcoma after breast-conservative therapy for early-stage breast cancer in a young woman with Li-Fraumeni syndrome.J Natl Compr Cancer Netw JNCCN. 2012; 10: 939-942
- Frequency of radiation-induced malignancies post-adjuvant radiotherapy for breast cancer in patients with Li-Fraumeni syndrome.Breast Cancer Res Treat. 2020; 181: 181-188
- Radiotherapy-induced malignancies in breast cancer patients with TP53 pathogenic germline variants (Li–Fraumeni syndrome).Fam Cancer. 2020; 19: 47-53
- Non-BRCA1/2 Breast Cancer Susceptibility Genes: A New Frontier with Clinical Consequences for Plastic Surgeons.Plast Reconstr Surg - Glob Open. 2017; 1: 1
- The ATM-dependent DNA Damage Signaling Pathway.Cold Spring Harb Symp Quant Biol. 2005; 1: 99-109
- Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy.Br J Cancer. 1997; 76: 1546-1549
- Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects.Radiother Oncol J Eur Soc Ther Radiol Oncol. 2003; 69: 155-160
- Tolerability of Breast Radiotherapy Among Carriers of ATM Germline Variants.JCO Precis Oncol. 2021; 5: 227-234
- Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor.Genes Chromosom Cancer. 2000; 27: 124-129
- Radiation exposure, the ATM Gene, and contralateral breast cancer in the women’s environmental cancer and radiation epidemiology study.J Natl Cancer Inst. 2010; 102: 475-483
- Individual patient data meta-analysis shows a significant association between the ATM rs1801516 SNP and toxicity after radiotherapy in 5456 breast and prostate cancer patients.Radiother Oncol. 2016; 121: 431-439
- Ataxia Telangiectasia-Mutated Gene Polymorphisms and Acute Normal Tissue Injuries in Cancer Patients After Radiation Therapy: A Systematic Review and Meta-analysis.Int J Radiat Oncol. 2015; 91: 1090-1098
- Possession of ATM Sequence Variants as Predictor for Late Normal Tissue Responses in Breast Cancer Patients Treated With Radiotherapy.Int J Radiat Oncol. 2007; 69: 677-684
- ATMHaplotypes and Cellular Response to DNA Damage: Association with Breast Cancer Risk and Clinical Radiosensitivity.Cancer Res. 2003; 63: 8717-8725
- ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects.Int J Radiat Oncol Biol Phys. 2002; 52: 606-613
- ATM sequence variants and risk of radiation-induced subcutaneous fibrosis after postmastectomy radiotherapy.Int J Radiat Oncol Biol Phys. 2006; 64: 776-783
- ATM, radiation, and the risk of second primary breast cancer.Int J Radiat Biol. 2017; 93: 1121-1127
- Identification of women with an increased risk of developing radiation-induced breast cancer: a case only study.Breast Cancer Res BCR. 2007; 9: R26
- Outcomes of adjuvant radiation therapy for breast cancer in women with ataxia-telangiectasia mutations.JAMA. 2001; 286: 2233-2234
- Clinical Interpretation of Pathogenic ATM and CHEK2 Variants on Multigene Panel Tests: Navigating Moderate Risk.Fam Cancer. 2018; 17: 495-505
- Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.Nat Genet. 2002; 31: 55-59
- Breast cancer in patients carrying a germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant radiotherapy.Radiother Oncol J Eur Soc Ther Radiol Oncol. 2007; 82: 349-353
- Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.Breast Cancer Res Treat. 2004; 83: 91-93
- Genetics of breast cancer: a topic in evolution.Ann Oncol. 2015; 26: 1291-1299
- TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer.Radiother Oncol. 2005; 75: 18-21
- Patients with a high polygenic risk of breast cancer do not have an increased risk of radiotherapy toxicity.Clin Cancer Res Off J Am Assoc Cancer Res. 2016; 22: 1413-1420
- Clinical practice guidelines for BRCA1 and BRCA2 genetic testing.Eur J Cancer Oxf Engl. 2021; 1990: 30-47
- 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5).Ann Oncol Off J Eur Soc Med Oncol. 2020; 31: 1623-1649
- Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS.Ann Oncol Off J Eur Soc Med Oncol. 2020; 31: 451-469
- Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021.Ann Oncol Off J Eur Soc Med Oncol. 2021; 32: 1216-1235
- p53 Status predicts survival in breast cancer patients treated with or without postoperative radiotherapy: a novel hypothesis based on clinical findings.J Clin Oncol. 2016; ([Internet][cited 2022 Jan 17])
- Breast cancer in female carriers of ATM gene alterations: outcome of adjuvant radiotherapy.Radiother Oncol. 2004; 72: 319-323
Article info
Publication history
Published online: September 19, 2022
Accepted:
September 11,
2022
Received in revised form:
August 30,
2022
Received:
April 20,
2022
Identification
Copyright
© 2022 Elsevier B.V. All rights reserved.
